SECOND AMENDMENT TO LEASELease • August 3rd, 2021 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 28th day of April, 2021, by and between BMR-FRESH POND RESEARCH PARK LLC, a Delaware limited liability company (“Landlord”), and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Alnylam – Tekmira...Supplemental Agreement • August 3rd, 2021 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • British Columbia
This Supplemental Agreement is made by and among Alnylam Pharmaceuticals, Inc. (“Alnylam”), Tekmira Pharmaceuticals Corporation (“Tekmira”), Protiva Biotherapeutics Inc., a wholly-owned subsidiary of Tekmira (“Protiva”), the University of British Columbia (“UBC”), and AlCana Technologies, Inc. (“AlCana”), as of the effective date stated above.
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SPONSORED...Research Agreement • August 3rd, 2021 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • British Columbia
THIS SPONSORED RESEARCH AGREEMENT (together with the attached Exhibits, the “Agreement”), dated as of July 27, 2009 (the “Effective Date”), is by and among Alnylam Pharmaceuticals, Inc., a Delaware corporation with a principal office at 300 Third Street, Cambridge, MA 02142, USA (“Alnylam”), The University of British Columbia, a corporation continued under the University Act of British Columbia, Canada, with offices at 103-6190 Agronomy Road, Vancouver, British Columbia, Canada (“UBC”) and AlCana Technologies, Inc., a British Columbia corporation with a principal business address at 2714 West 31st Avenue, Vancouver, British Columbia, Canada V6L 2A1 (“AlCana”). Each of Alnylam, UBC and AlCana may be referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NO. 1...Sponsored Research Agreement • August 3rd, 2021 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO SPONSORED RESEARCH AGREEMENT (this “Amendment No. 1”) dated as of July 27, 2011 (the “Effective Date”) is by and among Alnylam Pharmaceuticals, Inc., a Delaware corporation with a principal office at 300 Third Street, Cambridge, MA 02142, USA (“Alnylam”), The University of British Columbia, a corporation continued under the University Act of British Columbia, Canada, with offices at 103-6190 Agronomy Road, Vancouver, British Columbia, Canada (“UBC”) and AlCana Technologies, Inc., a British Columbia corporation with a principal business address at 2714 West 31st Avenue, Vancouver, British Columbia, Canada V6L 2A1 (“AlCana”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Sponsored Research Agreement (as defined herein).
